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Abstract
Background: Hepatocellular carcinoma (HCC) is a classical example of inflammation-linked cancer and is characterized by
hypervascularity suggesting rich angiogenesis. Cycloxygenase-2 (COX-2) is a potent mediator of inflammation and is
considered to upregulate angiogenesis. The aims of the study are (1) to analyze expression of Cox-2 mRNA, Cox-2 protein,
miR-16, miR-21 and miR-101 in HCC and adjacent liver parenchyma in cirrhotic and noncirrhotic liver, (2) to investigate the
relation between COX-2 expression, miR-21 expression and angiogenic factors in these tissues and (3) to investigate the
association between miR-16 and miR-101 and COX-2 expression.
Methods: Tissue samples of HCC and adjacent liver parenchyma of 21 noncirrhotic livers and 20 cirrhotic livers were
analyzed for COX-2 expression at the mRNA level (qRT-PCR) and at the protein level by Western blot and
immunohistochemistry. Gene expression of VEGFA, VEGFR1, VEGFR2, Ang-1, Ang-2 and Tie-2 were correlated with COX-2
levels. miR-16, miR-21 and miR-101 gene expression levels were quantified in HCC tumor tissue.
Results: COX-2 mRNA and protein levels were lower in HCC as compared to adjacent liver parenchyma both in cirrhotic and
noncirrhotic liver. COX-2 protein localized mainly in vascular and sinusoidal endothelial cells and in Kupffer cells. At the
mRNA level but not at the protein level, COX-2 correlated with mRNA levels of angiogenic factors VEGFR1, Ang-1, and Tie2.
miR-21 expression was higher in cirrhotic tissues versus noncirrhotic tissues. MiR-101 expression was lower in cirrhotic
versus noncirrhotic adjacent liver parenchyma. None of the miRNAs correlelated with COX-2 expression. miR-21 correlated
negatively with Tie-2 receptor in adjacent liver parenchyma.
Conclusions: In human HCC, COX-2 mRNA but not COX-2 protein levels are associated with expression levels of angiogenic
factors. MiR-21 levels are not associated with angiogenic molecules. MiR-16 and miR-101 levels do not correlate with COX-2
mRNA and protein levels.
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Introduction
More than 80% of hepatocellular carcinomas (HCC) are
associated with chronic infection caused by hepatitis B or C virus
[1]. In well-developed countries with a high incidence of obesity
and diabetes mellitus the risk of developing HCC rises propor-
tionally with increasing body mass index and the duration of
diabetes [2,3]. These conditions are frequently associated with
non-alcoholic steatohepatitis (NASH) [4,5]. The common denom-
inator in viral hepatitis associated liver diseases and NASH is
presumed to be the chronic inflammation leading to fibrosis and
cirrhosis and ultimately to HCC. HCC is thus one of the classical
examples of inflammation-linked cancer [6]. The cyclooxygenase-
2 (COX-2)- prostanoid pathway plays a pivotal role in inflamma-
tion and in the pathophysiology of liver diseases like cirrhosis and
HCC [7]. COX-2 is an inducible immediate-early gene originally
found to be induced by various stimuli including mitogens,
cytokines and growth factors [8]. COX-2 might favor tumor
growth by various mechanisms including stimulation of angiogen-
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esis, evasion of apoptosis and propensity to metastatic behavior
and invasion. COX-2 inhibitors can block these mechanisms by
various pathways and selective COX-2 inhibitors have been
evaluated for their effect on HCC cell growth and invasion using
animal models of hepatocarcinogenesis [9,10].
HCC can also arise in noncirrhotic livers with normal histology
and no signs of inflammation or viral hepatitis. A common
characteristic of both types of HCC is hypervascularity. The
occurrence of both types of HCC in humans offers a unique
opportunity to study the possible relation between inflammation
and angiogenesis, in which angiogenic characteristics can be
analyzed in the presence (cirrhotic HCC) or absence (noncirrhotic
HCC) of chronic inflammation. Unraveling of the underlying
mechanisms might lead to more efficacious treatment modalities
both for (chemo)prevention and possibly also for treatment of
already established HCC.
The aim of the present study is to investigate the correlation of
COX-2 expression with the expression of angiogenic factors in
human HCC in cirrhotic and noncirrhotic livers. We investigated
gene and protein expression levels of COX-2 and correlated these
to gene expression levels of VEGF-A, VEGFR-1 (Flt-1) and
VEGFR-2 (KDR), and Angiopoietin (Ang)-1, Ang-2, and their
receptor Tie-2 in HCC, adjacent liver parenchyma and normal
liver parenchyma. The cellular localization of COX-2 was studied
by immunohistochemistry. Several papers highlighted the role of
microRNAs (miRNAs) in the control of COX-2 transcription.
MiRNAs are small noncoding RNAs that control gene expression
at the posttranscriptional level. Their role in HCC has recently
been reviewed [11]. Especially miR-21, miR-101 and miR-16
seem to be relevant for the present study. MiR-21 is an oncogene
with high expression levels in various cancers including HCC.
Additionally, miR-21 is strongly related to angiogenesis [12,13].
Furthermore, accumulating evidence links miR-21 to inflamma-
tion [14–16] including the necroinflammation in the liver which
ultimately results in liver cirrhosis [17]. In contrast, miR-101 is
considered a tumor suppressor gene and its expression was
inversely correlated with COX-2 expression in colon cancer and
gastric cancer [18,19]. Another miRNA shown to inhibit COX-2
expression is miR-16. In several hepatoma cell lines an inverse
relation between miR-16 and COX-2 was found [20].The same
authors describe a negative correlation between COX-2 protein
and miR-16 expression in seven human HCC and paired non-
tumoral liver biopsies.
The study aimed at analysing (1) the correlation between COX-
2 expression and angiogenic factors, (2) the correlation between
COX-2 expression and miR-101/miR-16 and (3) the correlation
between angiogenic factors and miR-21 in cirrhotic and non-
cirrhotic HCC, both in tumor tissue and adjacent liver parenchy-
ma.
Patients and Methods
All (anonymised) tissue samples were processed according to
national guidelines. According to the Dutch law no approval of an
Institutional Review Board is necessary for investigations using
archival materials of previously resected tissue specimens. Tissue
samples of 41 HCC patients were included; 21 noncirrhotic HCC
obtained from partial liver resection specimens and 20 cirrhotic
HCC obtained from liver explants after liver transplantation.
Clinicopathological characteristics of the patients are summarised
in Table 1. A sample of adjacent, non-tumorous liver tissue was
also included in the study. None of the HCC patients underwent
previous treatments like local ablation, chemoembolisation or
chemotherapy.
Samples from histological normal livers (n = 8), obtained from
surplus donor liver or partial liver resection for benign disorders,
were used as a reference and not for statistical comparisons. HCCs
were graded according to the Edmonson classification and COX-2
mRNA level and protein expression was compared among the
three classes.
RNA extraction and quantitative reverse transcription
polymerase chain reaction (qRT-PCR)
Quantitative RT-PCR was performed as described previously
[21]. Intron overlapping primer sets and minor groove binder
probes were purchased as Assay-on-Demand from Applied
Biosystems (Nieuwekerk a/d IJssel, The Netherlands): housekeep-
ing gene GAPDH (assay ID Hs99999905_m1), COX-2 (assay ID
Hs00153133_m1), VEGF (Hs00173626_m1), VEGFR-1
(Hs00176573_m1), VEGFR-2 (Hs00176676_m1), Tie2 (assay ID
Hs00176096_ml), Ang-1 (assay ID Hs00181613_ml), Ang-2 (assay
ID Hs00169867_ml).
MiRNA analysis
Expression levels of miR-16, miR-21 and miR-101 were
determined by qRT-PCR using RNU49 as housekeeping gene
with miRNA qRT-PCR assays (Applied Biosystems, Foster City,
USA) as described previously [22]. Reverse transcription (RT)
primers specific for a miRNA and RNU49 were multiplexed in
15 ml RT reactions containing 1 ml of each RT primer. The
miRNA levels were normalized to the RNU49 levels. Mean cycle
threshold (Ct) values for all genes were quantified with the SDS
software (version 2.1). Relative expression levels were calculated as
22DCt.
Western blot
Western blotting was performed as described previously using
mouse anti-COX-2, 1:500 (BD Biosciences Pharmingen,
#610204) [21]. Quantification of the signals detected was done
by relating COX-2 to b-actin control. The bands of COX-2
protein located at about 70 kDa as expected according to the
datasheet of the antibody.
Immunohistochemical examination of COX-2 expression
Four mm tissue sections were deparaffinized and treated with
0.08% H2O2 for 30 min to block endogenous peroxidase. Slides
were incubated with mouse anti-COX-2 (BD Biosciences
Pharmingen, #610204) 1:50, diluted in 1%BSA/PBS, at 4uC
overnight followed by incubation with horseradish peroxidase-
conjugated rabbit anti-mouse Ig and goat anti-rabbit Ig (DAKO),
both 1:100 diluted in 1%BSA/1% albumin/PBS. Diaminobenzi-
din was used to develop the staining reaction and nuclear
counterstaining was performed with haematoxylin. A sample of
a human colonic adenocarcinoma was included as a positive
control.
Correlation between COX-2 protein and mRNA level
Pearson correlation coefficients were calculated for COX-2
mRNA and COX-2 protein separately for HCC and liver
parenchyma. We calculated the COX-2 protein:COX-2 mRNA
ratio for each individual case; this method has been used for
identification of the strength of correlation of mRNA expression
and protein level of individual genes by Pradet et al [23].
Correlation of COX-2 and miR-21 with Ang-2:Ang1 ratio
Although in many tumors both Ang-1 and Ang-2 are elevated,
the angiogenic state of hypervascular tumors is characterized by
COX-2, miRNA and Angiogenesis in Human HCC
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an overexpression of Ang-2 in relation to Ang-1 thus creating a
shift in the Ang-2:Ang-1 ratio in favor of Ang-2 [24]. A higher
Ang2:Ang1 ratio was also encountered in human HCC [24].
Therefore we analyzed the correlation between COX-2, miR-
21and the Ang-2:Ang-1 gene expression ratio.
Statistical analysis
Quantitative data were expressed as median and interquartile
range (IQR). Expression of COX-2 mRNA, COX-2 protein, miR-
16, miR-21 and miR-101 were compared using a two-tailed
Mann-Whitney-U test (non-related samples) in cirrhotic versus
noncirrhotic liver of HCC and adjacent parenchyma separately.
The Wilcoxon test (related samples) was used for comparison of
HCC with adjacent parenchyma in cirrhotic and noncirrhotic
liver separately. For correlation statistics, values were normalised
by log (base 10) transformation. Pearson correlation coefficients
were calculated between COX-2 and the angiogenic factors,
between miR-21 and the angiogenic factors and between miR-101
and miR-16 and both COX-2 mRNA and COX-2 protein. A p-
value ,0.05 was considered significant.
Results
COX-2 expression in HCC and adjacent liver parenchyma
in cirrhotic and noncirrhotic liver
HCC tumor tissue in both cirrhotic and noncirrhotic liver
demonstrated a lower COX-2 expression compared to adjacent
parenchyma, both at the mRNA (Figure 1A) and protein level
(Figure 1B). Median COX-2 mRNA level in the tumor in
noncirrhotic liver was about tenfold lower than in tumor-adjacent
liver parenchyma (p,0.001). In cirrhotic liver, HCC tumor had a
six-fold lower COX-2 mRNA content than adjacent parenchyma
(p,0.001). Protein levels of COX-2 were approximately 370 fold
lower in HCC in noncirrhotic liver as compared to adjacent liver
parenchyma (p= 0.033). In cirrhotic liver, HCC tumor had a 30%
lower COX-2 protein level (p = 0.020) than adjacent parenchyma.
A comparison between COX-2 mRNA and COX-2 protein
expression in cirrhotic versus noncirrhotic HCC tumor tissue
revealed no differences (Figures 1A and 1B). COX-2 staining in
HCC was mainly found in endothelial cells lining the sinusoid-like
spaces in the tumor but less conspicuous than in vascular
endothelial cells at the interface between tumor and adjacent
liver parenchyma. (Figure 2) As a positive control of COX-2
immunohistochemical staining we included a colon carcinoma
sample which was strongly positive (Figure 2 insert). No difference
was found in COX-2 mRNA level and protein expression between
tumors with Edmonson grade 1, grade 2 or grade 3 (p.0.35).
COX-2 mRNA and COX-2 protein expression in tumor-
adjacent liver parenchyma was comparable in cirrhotic and in
noncirrhotic liver and in the same range as normal liver
parenchyma (Figures 1A and 1B). COX-2 staining was observed
in both vascular and sinusoidal endothelial cells as well as in
Kupffer cells in normal liver and in parenchyma adjacent to HCC.
No expression was found in hepatocytes or in cholangiocytes
(Figure 2).
Although median COX-2 expression in HCC was less than in
the surrounding parenchyma, individual cases demonstrated
variable results as can also be seen in representative Western
blots of COX-2 (Figure 3).
Correlation of COX-2 gene expression and protein level
with angiogenic factors in HCC tumor tissue
Of the six analysed angiogenic factors, VEGFR1, Ang-1 and
Tie-2 revealed a significant correlation with COX-2 mRNA levels
in HCC tumor tissue both in noncirrhotic and cirrhotic liver
(Table 2). Additionally, a correlation between COX-2 mRNA and
VEGFR2 mRNA was observed in HCC in noncirrhotic liver only
(r = .78, p,0.001). No significant correlations were obtained
between the angiogenic factors and COX-2 protein in HCC
tumor tissue. Moreover, also the Ang-2:Ang-1 gene expression
ratio did not show any correlation with COX-2 expression
(Table 2).
Correlation of COX-2 gene expression and protein level
with angiogenic factors in adjacent liver parenchyma
We found no significant correlation between COX-2 mRNA
levels and any of the angiogenic factors in tumor-adjacent liver
parenchyma, except for Ang-1 in adjacent cirrhotic liver (Table 2).
None of the mRNA levels of the angiogenic factors in adjacent
parenchyma correlated significantly with COX-2 protein.
Table 1. Clinicopathological characteristics of the cirrhotic and noncirrhotic patient group.
Clinicopathological variable Noncirrhotic Cirrhotic
n =21 n=20
Sex (male/female) 13/8 15/5
Underlying liver disease Absent HCV 4
Alcoholic liver disease 3
cryptogenic 3
hemochromatosis 2
metabolic disease 1 5
various 3
Age median (IQR) 56.3 (27.5) 58.6 (10.8)
a-fetoprotein (mg/L; median (IQR)) 7.0 (428) 17 (44)
Largest HCC diameter (cm; median (IQR)) 13.0 (10) 3.5 (2)
Number of HCC nodules median (IQR) 1 (0) 2 (6)
1a1-antitrypsin deficiency (n = 2); glycogenosis type III (n = 1); tyrosinemia (n = 2).
doi:10.1371/journal.pone.0095826.t001
COX-2, miRNA and Angiogenesis in Human HCC
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Figure 1. Plots representing relative expression of COX-2 mRNA (A), COX-2 protein (B), miR-16 (C), miR-21 (D) and miR-101 (E) in in
normal liver, HCC tumor tissue (T) and tumor-adjacent parenchyma (Ad) in noncirrhotic and in cirrhotic liver. Median values and 25th–
75th percentiles are shown. P-values: *,0.05; **,0.01; ***,0.001.
doi:10.1371/journal.pone.0095826.g001
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Correlation of COX-2 mRNA expression and COX-2
protein level
No correlation was found between COX-2 mRNA expression
and COX-2 protein level neither in HCC tumor tissue nor in
adjacent parenchyma (p.0.13). Calculation of the COX-2
protein:COX-2 mRNA ratio revealed a range from ,1 to
.35,000 in HCC tumor tissue and from 100 to .7,000 in liver
parenchyma. These results suggest that post-transcriptional
mechanisms are responsible for the highly variable COX-2
protein levels.
MiR-16 expression in HCC and liver parenchyma and
correlation with COX-2 expression
Figure 1C shows the relative expression of miR-16 in normal
liver, tumor adjacent liver and in cirrhotic and noncirrhotic HCC
tumor tissue. No statistically significant differences were found
between any of these tissues. Also no correlation between miR-16
expression and either COX-2 mRNA or COX-2 protein was
found.
MiR-21 expression in HCC and liver parenchyma and
correlation with angiogenic factors
Relative expression levels of miR-21 were higher in cirrhotic
tissues –both in HCC tumor tissue and adjacent liver parenchyma-
as compared to HCC and parenchyma in non-cirrhotic tissues
(Figure 1D). Furthermore, HCC in cirrhotic liver revealed a
higher expression of miR-21 versus adjacent liver parenchyma.
Analyzing the correlation between miR-21 expression and the
angiogenic factors revealed no correlations except for a negative
correlation (r =2.76, p = 0.046) between miR-21 expression and
the Tie-2 receptor in adjacent cirrhotic liver parenchyma.
MiR-101 expression in HCC and liver parenchyma and
correlation with Cox-2 expression
Relative expression levels of miR-101 were lower in adjacent
liver parenchyma in cirrhotic liver as compared to adjacent
parenchyma in non-cirrhotic liver (Figure 1E). MiR-101 expres-
sion did not correlate with COX-2 expression neither at the
mRNA level nor at the protein level.
Discussion
In this study we analyzed the expression of COX-2, miR-101
and miR-16 -both with COX-2 inhibiting effects- and miR-21 -
with pro-angiogenic and pro-inflammatory effects- in relation to
expression of various angiogenic factors in human HCC in
cirrhotic and noncirrhotic liver. The chronic inflammation in
cirrhotic liver provides a prosperous environment for development
of HCC and because of the interaction between inflammation and
angiogenesis we analysed the above mentioned molecules in two
groups of patients; those with HCC in a cirrhotic liver and in
patients with HCC in a noncirrhotic liver. The main finding of this
study is that although at mRNA level COX-2 expression correlates
positively with mRNA expression of the Ang-1/Tie-2 axis in both
cirrhotic and noncirrhotic HCC, no such a correlation was
encountered at the COX-2 protein level. As a possible explanation
for this discrepancy we investigated the role of miR-101 and miR-
16 in HCC tumor tissue and adjacent parenchyma. We found that
Figure 2. COX-2 immunostaining on HCC (upper left, marked
with *) and adjacent liver parenchyma (lower right, marked
with @). COX-2 expression is present on endothelial cells (arrows) at
the interface between HCC and non-tumorous liver parenchyma. In the
liver parenchyma COX-2 expression is mainly present in Kupffer cells
and some inflammatory cells. Note the absence of staining in
hepatocytes and tumor cells. The insert (lower right hand corner)
shows COX-2 immunostaining on coloncarcinoma as a positive control.
doi:10.1371/journal.pone.0095826.g002
Figure 3. Example of representative cases analysed in this study showing Western blot of COX-2 in matched pairs of 11
noncirrhotic (upper panel) and 8 cirrhotic (lower panel) samples of HCC and tumor-adjacent liver parenchyma. (Adj: tumor-adjacent
liver parenchyma; T: tumor (HCC)).
doi:10.1371/journal.pone.0095826.g003
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neither miR-101 nor miR-16 had a correlation with COX-2
mRNA or COX-2 protein.
In prostate cancer cell lines it was demonstrated that miR-101
inhibits COX-2 by translational repression via binding to the 39
untranslated region (UTR) of COX-2 mRNA [25]. In colon
cancer cell lines a discrepancy was encountered between COX-2
protein levels and COX-2 mRNA expression; of six miRNAs
examined only miR-101 demonstrated an inverse relation with the
COX-2 protein/mRNA ratio in these cell lines [18]. The same
authors investigated human primary colorectal cancer specimens
and liver metastases and found the same inverse relation. In a
series of 30 patients with gastric cancer more advanced tumor
stages were associated with lower miR-101 expression which was
inversely related to COX-2 mRNA expression [19]. All these data
provide support for a possible role of miR-101 as a negative
regulator of COX-2 protein expression and therefore we analyzed
this interaction also in the HCC tumor tissue. However, we could
not corroborate these findings since our data showed no inverse
correlation between COX-2 and miR-101 in HCC.
MiR-21 is an important oncomir in many cancers and also in
HCC tumor tissue [26,27]. MiR-21 plays a role in angiogenesis as
was demonstrated in experiments with cell lines as well as in
human cancer [12,13]. In prostate cancer cell lines inhibition of
miR-21 was associated with a less aggressive phenotype via
inhibition of tumor growth and invasiveness [28]. Of the miRNAs
analysed in our study, the most prominent differences were
encountered in miR-21 expression. MiR-21 revealed the highest
expression in HCC in cirrhotic liver and also adjacent cirrhotic
liver parenchyma showed a higher miR-21 expression as
compared to noncirrhotic adjacenct liver parenchyma. This
differential expression, however, did not translate into significant
correlations with the studied angiogenic factors, except for a
negative correlation with the Tie-2 receptor in liver parenchyma
only. This adds support to the idea that clinically overt HCC –
despite a different parenchymal background- share several
molecular characteristics, which is in accordance with previous
findings in which no differences were found between HCC in
cirrhotic versus noncirrhotic livers with respect to endothelial cell
turnover, microvessel density as well as expression of various
angiogenic growth factors [29,30]. MiR-21 is rather ubiquitous in
health and disease [14,31]. Therefore it is not surprising that
upregulation of miR-21 has a pivotal role in many inflammatory
processes, like in patients with chronic liver diseases in whom miR-
21 serum levels correlated with the severity of liver fibrosis and
necroinflammation [17,32].
We found a discordance between COX-2 mRNA and protein
level. As a possible explanation for this discrepancy post-
transcriptional mechanisms, like transcript decay and translation
rate, but also post-translational modifications which determine
protein turnover and thereby protein expression levels have been
described [33][34]. In humans highly discrepant results were
observed between mRNA and protein expression in a study of
human lung adenocarcinomas [35]. Thus, mRNA abundance
does not necessarily translate into the detection of the correspond-
ing protein with the currently available techniques and conclusions
should be drawn cautiously [23].
The lack of correlation between miR-16, miR-101 and COX-2
expression is in contrast to findings in other tumor types like
gastric and colon cancer. We propose two possible explanations
for this discrepancy, (1) insufficient expression level of the miRNAs
and (2) (tumor)tissue specificity of the miRNAs. It is likely that the
expression of miRNAs should be above a –as yet unknown-
minimum threshold level before they can exert their function
[36,37]. Differences in miRNA expression might thus explain
differences in functional actvivity. In addition, the overall
abundance of all miRNA specific target genes in a given cell also
may affect the targeting efficiency. For the analysis at the RNA
level total tissue is used, and there might be a discrepancy between
cells expressing the miRNA and the COX-2 gene. The current
dogma describes that COX-1 is constitutively expressed and
COX-2 is only expressed as a result of induction by a wide range
of stimuli [38]. In an autopsy study on trauma victims, this concept
was seriously questioned, because several healthy tissues, including
the normal liver, were shown to express COX-2 [39]. We also
found COX-2 expression in normal liver parenchyma; this was
comparable to COX-2 expression in liver parenchyma adjacent to
HCCs. In parenchyma adjacent to HCC we found that COX-2
expression was even higher than in HCC itself. Our data are in
agreement with findings of Morinaga et al. who found a 2.5- fold
higher COX-2 mRNA expression in adjacent liver parenchyma as
Table 2. Correlation between COX-2 mRNA and protein level with mRNA level of various angiogenic factors.
Noncirrhotic liver Cirrhotic liver
mRNA level
angiogenic
factor COX-2 mRNA COX-2 protein COX-2 mRNA COX-2 protein
tumor adjacent tumor adjacent tumor adjacent tumor adjacent
r p r p r p r p r p r p r p r p
VEGFA .39 .08 .09 .79 2.57 .07 .05 .88 .26 .21 .20 .36 205 .81 .11 .62
VEGFR1 .86. .001 2.24 .49 2.48 .13 .54 .09 .48 .02 .08 .71 .09 .70 .06 .78
VEGFR2 .78 .001 .37 .26 2.47 .14 2.27 .42 .16 .44 2.05 .81 2.12 .60 2.38 .09
Ang-1 .51 .02 .15 .67 2.13 .71 2.23 .49 .51 .01 .42 .04 .22 .32 2.02 .95
Ang-2 .13 .58 2.12 .73 2.41 .21 .21 .54 .08 .72 .24 .27 .11 .63 .08 .71
Tie-2 .82 .001 2.22 .51 2.42 .20 2.42 .20 .68 .001 .21 .35 .18 .42 2.08 .73
Ang-2:Ang-1 2.40 .07 2.18 .60 2.3 .37 .34 .31 2.36 .08 .24 .27 2.14 .53 .08 .71
Pearson r (r) and p-value (p) are presented in tumor and adjacent cirrhotic and noncirrhotic liver separately. Statistically significant correlations are shown in bold.
Abbreviations: Ang-1/2: angiopoietin-1/2; Tie-2: tyrosine kinase with immunoglobulin-like and EGF-like domains-2; COX-2: Cycloxygenase-2; mRNA: messenger
ribonucleic acid; VEGFA: vascular endothelial growth factor A, VEGFR1/R2: vascular endothelial growth factor receptor K; Tu: tumor; Adj: adjacent.
doi:10.1371/journal.pone.0095826.t002
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compared to HCC [40]. In their study COX-2 protein expression
-determined by immunohistochemistry- seemed to parallel mRNA
expression and the authors explained this by inflammatory activity
in tumor-adjacent parenchyma.
A limitation of our study is that the investigated tumor samples
were obtained from clinically overt HCCs and the resulting
signature will be rather different from the signature in dysplastic
nodules and small –clinically undetectable- HCCs. For instance,
COX-2 expression was found to be highest in dysplastic nodules
with lower expression levels in more poorly differentiated
advanced tumors in human HCC [41]. Another limitation of
the study is the relatively low number of included patient samples.
From this study in human HCCs we conclude that COX-2 is
expressed to a similar extent in cirrhotic and noncirrhotic adjacent
liver parenchyma. Also no differences were found between HCC
in cirrhotic and noncirrhotic liver despite the fact that COX-2
mRNA and COX-2 protein was lower in HCC in comparison to
adjacent parenchyma. COX-2 mRNA levels both in cirrhotic and
noncirrhotic HCC tumor tissue correlated with angiogenic factors.
The inverse correlation between miR-101 and COX-2 protein –as
found in colorectal cancer by others- was not found in our HCC
tumor samples. The described prominent role of miR-21 as a pro-
angiogenic miR could not be substantiated in this study. The
clinical usefulness of COX-2 inhibitors especially in the setting of
chemoprevention for the development of human HCC can only
be based on randomized clinical trials since the precise regulatory
mechanisms of COX-2 are far from elucidated.
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